LEU › analyze
LEU · Analyze
Date: 2026-06-11 | Price: ~$157.77 | 52wk Range: $144.65 – $464.25 | Market Cap: ~$3.1B | Sector: Energy / Uranium (Enrichment & Technical Solutions)
Manager Dispatch Summary
Centrus is the only U.S.-licensed HALEU producer with a $3.9B backlog extending to 2040. The stock is down 66% from its $464 October 2025 ATH — not because the thesis broke, but because the company is now actually spending billions to build the capacity the market was previously just pricing as narrative. Q1 2026 showed earnings compression from expansion costs; the market punished that. At ~$157 ($144 52wk low hit this week), the price is near base-case fair value. Standard valuation models (Graham: $58 target) all say "overvalued" — but they're measuring the wrong thing. The correct lens is backlog coverage, strategic monopoly value, and DOE commitment. Verdict: [7.5/10] — Add at $145–170. This is a hold/add, not a trim.
Phase 1 — Fundamentals Analyst
Revenue & Income (FY = December 31)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $293.8M | $320.2M | $442.0M | $448.7M |
| Gross Profit | $117.9M | $112.1M | $111.5M | $117.5M |
| Gross Margin | 40.1% | 35.0% | 25.2% | 26.2% |
| Operating Income | $60.2M | $52.4M | $48.0M | $50.2M |
| Operating Margin | 20.5% | 16.4% | 10.9% | 11.2% |
| Reported Net Income | $52.2M | $84.4M | $73.2M | $77.8M |
| Normalized Net Income | $51.0M | $75.7M | $63.0M | $27.0M |
| Diluted EPS | $3.38 | $5.44 | $4.47 | $3.90 |
Gross margin compression is the central financial story. Revenue grew 53% from FY2022 to FY2025, but gross margin fell from 40.1% to 26.2% — cost of revenue is growing faster than revenue as the company ramps enrichment purchases to fulfill expanded contracts. Operating margin has more than halved from 20.5% to 11.2%.
Reported vs. normalized: Net income looks solid at $77.8M, but $44.7M of that is a "Gain on Sale of Securities" — a non-recurring item. Normalized operating earnings are ~$27M for FY2025. The earnings quality has declined significantly.
Q1 2026 (most recent): - Revenue: $76.7M (+5% YoY) — slightly below $78.3M estimate - Net income: $10.0M (-63.2% YoY) - Adj. EPS diluted: $1.05 (vs. $1.60 prior year) - FY2026 guidance raised: $450–500M revenue (from $425–475M) - Backlog: $3.9B ($3.1B LEU + $0.8B Technical Solutions, extends to 2040) - Technical Solutions revenue: $32.1M (up from $21.8M — HALEU contract contribution)
Revenue & Earnings CAGRs (FY2022–FY2025, 3yr)
| Metric | CAGR |
|---|---|
| Revenue | +15.2% |
| Net Income (reported) | +14.2% |
| Diluted EPS | +4.9% (diluted by share issuance) |
| FCF | +16.3% |
Revenue and FCF are growing in the mid-teens — solid for a strategic infrastructure company. But EPS growth is lagging due to significant share dilution from capital raises.
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Operating Cash Flow | $20.6M | $9.1M | $37.0M | $51.0M |
| CapEx | -$0.7M | -$1.6M | -$4.1M | -$19.7M |
| Free Cash Flow | $19.9M | $7.5M | $32.9M | $31.3M |
| Equity Raised | $3.6M | $23.2M | $54.7M | $523.7M |
| Debt Issued | — | — | $388.7M | $782.4M |
FCF has been modestly positive ($20-33M range) and improving from operations. But FY2025 saw massive capital raises: $523.7M equity + $782.4M debt = $1.306B raised to fund the Piketon expansion. CapEx jumped from $4.1M to $19.7M — this is just the beginning; expect CapEx to accelerate sharply through 2026-2031 as Piketon construction proceeds.
Capital allocation (FY2025): - Piketon/Oak Ridge expansion investment: majority of $1.3B raised - Zero dividends, zero buybacks - Debt service: $14M interest expense (FY2025, up from $2.7M in FY2024) - Operating business: self-funding via OCF
Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Cash & Equivalents | $179.9M | $201.2M | $671.4M | $1,957.2M |
| Total Financial Debt | $163.7M | $174.5M | $546.0M | $1,215.2M |
| Net Cash (Debt) | +$16.2M | +$26.7M | +$125.4M | +$742.0M |
| Total Assets | $705.5M | $796.2M | $1,093.4M | $2,445.9M |
| Stockholders' Equity | -$74.1M | $32.3M | $161.4M | $765.1M |
| BVPS | — | $2.06 | $9.62 | $38.91 |
| Debt/Assets | 23.2% | 21.9% | 49.9% | 49.7% |
| Working Capital | $137.9M | $214.3M | $668.4M | $1,940.8M |
The balance sheet transformation is dramatic. Equity was negative as recently as FY2022. The $1.3B capital raise in FY2025 created a fortress: $742M net cash, $1.94B working capital. The company is well-capitalized for the expansion — a second major equity raise in the near term seems unlikely given this cushion.
Debt/Assets at 49.7% is elevated but not alarming given the net cash position. The real risk is interest expense: $14M in FY2025, likely $60-80M+ in 2026 on a full-year basis with $1.2B outstanding.
Shares Outstanding (Dilution Tracker)
| Date | Shares | Δ vs. FY2022 |
|---|---|---|
| FY2022 | 14.64M | — |
| FY2023 | 15.68M | +7.1% |
| FY2024 | 16.77M | +14.6% |
| FY2025 | 19.66M | +34.3% |
The FY2025 equity raise added ~3M shares at what appears to be ~$175/share average. This is notable dilution but at a premium to current prices. Watch for further dilution as Piketon construction ramps.
Per-Share Metrics
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue/Share | $20.07 | $20.42 | $26.36 | $22.82 |
| FCF/Share | $1.36 | $0.48 | $1.96 | $1.59 |
| Net Cash/Share | $1.11 | $1.70 | $7.48 | $37.74 |
| Backlog/Share (Q1 2026) | — | — | — | ~$198 |
The backlog/share figure is striking: $3.9B backlog ÷ ~19.7M shares = ~$198/share in contracted future revenue. At today's price of $157, you're paying less than backlog per share before accounting for the business's going-concern value, net cash, and strategic position.
Phase 1 — Sentiment Analyst
Analyst Consensus
| Period | Strong Buy | Buy | Hold | Sell |
|---|---|---|---|---|
| Current | 2 | 9 | 5 | 0 |
| -1 Month | 2 | 9 | 5 | 0 |
| -2 Month | 2 | 9 | 5 | 0 |
| -3 Month | 2 | 9 | 5 | 0 |
11 Buy, 5 Hold, 0 Sell — stable for 3 months. Despite the 66% price decline from the ATH, no analyst has downgraded to Sell. Citigroup reduced its price target to $218 (from $224) while maintaining Neutral — that's 38% above today's price even from the most conservative firm.
Q1 2026 Earnings Breakdown (May 5, 2026)
Results vs. expectations: | Metric | Q1 2025 | Q1 2026 | Δ YoY | vs. Est. | |--------|---------|---------|-------|---------| | Revenue | $73.0M | $76.7M | +5.0% | $78.3M (miss) | | Net Income | $27.2M | $10.0M | -63.2% | — | | Adj. EPS diluted | ~$1.60 | $1.05 | -34.4% | — | | Tech Solutions Rev. | $21.8M | $32.1M | +47.2% | ↑ (HALEU growing) |
Initial reaction: Stock +12% immediately post-earnings on guidance raise + backlog growth. But enthusiasm faded throughout May (-13.5% for the month) as investors focused on the earnings miss.
Strategic Catalysts (2026)
| Catalyst | Details | Impact |
|---|---|---|
| $900M DOE HALEU Award | Jan 6, 2026. Task order to expand Piketon to commercial-scale HALEU. Can exceed $1B. Contract through Jan 2031. | 🟢 Transformative — government as anchor customer |
| Fluor as EPC | Feb 2026. Fluor leads engineering, procurement, and construction of Piketon expansion. Multiyear strategic collaboration. | 🟢 Execution credibility |
| Geiger Brothers construction | Apr 2026. On-the-ground construction contractor for Piketon. $900M cap, time-and-materials through Jan 2031. | 🟢 Boots on ground — expansion moving from planning to execution |
| Oak Ridge $560M expansion | Centrifuge manufacturing plant expansion. Identified $300M in cost savings via AI/automation. | 🟢 Supply chain secured for centrifuges |
| Oklo JV exploration | Deconversion services JV for HALEU. Oklo is Sam Altman-backed; would add commercial nuclear fuel cycle service. | 🔵 Early-stage; optionality |
| FY2026 Revenue Guide | $450–500M (raised from $425–475M) | 🟢 Management confidence in near-term execution |
Price Action & Selloff Analysis
The price story in one line: $23 (Jan 2022) → $464 (Oct 2025 ATH) → $145 52wk low (June 9, 2026) → $157 today.
The selloff was driven by four compounding factors: 1. Earnings compression: Q1 2026 adj. EPS $1.05 vs. $1.60 prior year (-34%). The market had priced LEU as a high-multiple growth compounder; actual earnings are declining while expansion costs ramp. 2. Interest expense surge: $14M in FY2025 (full $1.2B debt load only partially for full year). FY2026 will carry ~$60-80M+ in interest, which alone will wipe out much of operating income without offset from new business. 3. Uranium spot price pullback: Spot moved from $101/lb (Jan 2026) to ~$86 (current). Correlated with sector sentiment. 4. Post-hype derating: The stock ran from $23 to $464 — a 20x in 4 years, much of it speculative multiple expansion. Normal gravity pulled the multiple back toward fundamentals once earnings peaked.
What did NOT change: The thesis — HALEU monopoly, $3.9B backlog, DOE funding, strategic national security position — is intact. The selloff is repricing the speculative premium, not pricing in a broken thesis.
Phase 2 — Moat Analyst
ROIC & Margin Trends
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Gross Margin | 40.1% | 35.0% | 25.2% | 26.2% |
| Operating Margin | 20.5% | 16.4% | 10.9% | 11.2% |
| Net Margin | 17.8% | 26.4% | 16.6% | 17.3% |
ROIC is difficult to compute meaningfully because invested capital has ballooned due to the Piketon capital raise. Using FY2025: Operating Income $50.2M / Invested Capital $1,978.8M = 2.5% ROIC — terrible in isolation, but the capital is parked in cash (not yet deployed to productive assets). Once deployed, ROIC should normalize substantially.
Competitive Moat Assessment
Moat Grade: 8.5/10 — Wide Moat (Regulatory Monopoly)
Primary moat: HALEU regulatory monopoly (durable, ~10-year lead)
Centrus is the sole U.S. Nuclear Regulatory Commission (NRC) licensed producer of HALEU for both commercial and national security applications. This is not just a competitive advantage — it is a statutory monopoly protected by: - 20+ years and $3.9B in sunk R&D costs for the American Centrifuge technology - 3.9 million machine-hours of operating experience - Domestic-only technology: centrifuges manufactured in Oak Ridge, TN with no foreign IP or components - U.S. government explicit requirement for domestic-origin technology in defense applications
Closest competitive timeline: - Orano USA: Planning LEU production by 2031, with NRC license submission in early 2026. Even in the optimistic scenario, they are 5+ years behind. - Urenco USA: Expanding existing capacity (+50% announced June 2026), but primarily LEU, not HALEU-capable. On current technology pathway, HALEU capability is post-2030. - General Atomics, X-energy: HALEU development stage, no production license.
Centrus has a 5-7 year structural monopoly on domestic HALEU before any competitor can produce at commercial scale. In strategic national security terms, this is essentially permanent until geopolitical conditions change.
Secondary moat: Deferred revenue / long-term contracts
The $3.9B backlog (extending to 2040) is not just a pipeline — it's contractual committed revenue. Customers (primarily utilities and the U.S. government) have locked in supply at negotiated prices. This creates revenue visibility that is rare for an energy company and means: - Centrus does not need to "win" new business to sustain the base; it just needs to deliver - Backlog will likely grow: utilities are structurally under-contracted; procurement wave is building - The 2040 duration means some contracts will reprice at higher uranium prices as contracts roll over
Tertiary moat: DOE anchor customer relationship
The Department of Energy is not just a contract customer — it is a strategic partner. The $900M+ HALEU task order is a strategic national security investment, not a normal commercial contract. If LEU execution falters, DOE has every incentive to support the company (financially, technically, and through regulatory assistance) because there is no alternative. This creates an implicit floor on the business.
Adversarial Stress Test
"How does a rational competitor attack Centrus?"
-
Orano/Urenco fast-track: Redirect government resources, hire Centrus engineers, attempt to obtain NRC license faster. Counter: NRC licensing for HALEU is a multi-year process with national security dimensions; fast-tracking is unlikely. Centrus's 20-year head start in American Centrifuge is hard to leapfrog.
-
Policy reversal: New administration de-emphasizes domestic enrichment, allows Russian/Kazakh imports. Counter: Section 232 (uranium = national security asset) is embedded in executive order framework. HALEU for defense applications (submarines, defense reactors) is bipartisan and would not be reversed — it's not energy policy, it's defense policy.
-
Technology disruption: New enrichment technology makes centrifuges obsolete. Counter: Centrifuge technology is the dominant global enrichment method, used by all major enrichers. Lasers (GE-Hitachi SILEX) are decades from commercial scale. This threat is distant.
-
Cost overruns: Piketon expansion runs 30-50% over budget, requiring another equity raise at lower prices. Counter: Fluor (experienced nuclear EPC) and Geiger Brothers both engaged. $300M in identified cost savings. With $742M net cash, moderate overruns are absorbable. This is the most realistic risk.
Evergreen Rating: 8/10
Centrus's enrichment position is the most durable moat in the nuclear fuel supply chain. Unlike uranium mining (commodity product, global competition), enrichment requires technology-specific regulatory authorization that takes decades to develop. The NRC HALEU license is functionally a government-issued permanent franchise. Moderated to 8 (not 10) because: regulatory moat requires continued DOE support; Piketon execution is unproven at scale; and in 10+ years, competitors will enter.
Phase 2 — Valuation Analyst
Standard Model Results
Graham's Number (manual): EPS $3.90 (FY2025 diluted), BVPS $38.91 → √(22.5 × $3.90 × $38.91) = $58.45 Current price $157.77 = 2.70x Graham's Number → Significantly overvalued on this measure.
Caveat: Graham's Number is designed for stable, profitable industrial/consumer companies. It fundamentally cannot price a strategic infrastructure monopoly that is trading its near-term earnings for a $3.9B backlog and a government-endorsed expansion that represents decades of future value. Using Graham's Number for LEU is like using it for Amazon in 2005.
DDM / DYT: Not applicable — no dividend paid, no dividend history.
Bogle Expected Return: Not applicable — earnings declining near-term, no dividend yield, multiple expansion/contraction depends on expansion success.
Applicable Framework: Strategic Asset Valuation
Method 1 — EV/Backlog
| Metric | Value |
|---|---|
| Market Cap | $3.09B |
| Net Cash (Cash - Total Debt) | +$742M |
| Enterprise Value (EV) | ~$2.35B |
| Confirmed Backlog | $3.9B (to 2040) |
| EV / Backlog | 0.60x |
A 0.60x EV/backlog ratio is extremely low for a regulated infrastructure provider with a government anchor customer. Defense contractors and long-cycle energy infrastructure companies typically trade at 0.8–1.5x backlog. At 1.0x: fair value ~$3.9B EV + $742M net cash = $4.64B market cap → $236/share. At 0.8x: ~$3.12B EV + $742M = $3.86B → $196/share.
Method 2 — Forward Earnings (FY2027 Normalized)
As expansion costs roll off and Piketon begins generating revenue: - FY2027E revenue: $475–550M (midpoint $510M) - Operating margin recovery to 15-17% (vs. current 11.2%): Operating income $75–90M - Less interest expense (~$70M FY2027): Net operating income ~$5–20M from operations PLUS ~$50M from HALEU contracts - Estimated adj. EPS FY2027: $2.50–4.50 (wide range due to expansion ramp uncertainty) - At 35–45x P/E (strategic monopoly premium): $87–202/share
Fair Value Range:
| Scenario | Driver | Fair Value |
|---|---|---|
| Bear | Expansion delays, interest burden squeezes earnings, HALEU ramp slow | $90–115/share |
| Base | Expansion on track, backlog delivers $450–500M revenue, margins begin recovering | $155–200/share |
| Bull | Piketon ahead of schedule, new utility contracts push backlog to $5B+, HALEU commercial demand exceeds DOE | $250–320/share |
Current price $157 is at the floor of the base case. The 52wk low at $144.65 represents a bear-case level — at that price, you're essentially paying for just the current business cash flows with zero credit for the expansion.
Phase 3 — Tension / Debate
Tension: Valuation (cautious) vs. Moat + Backlog (strongly bullish)
Valuation Analyst opens: "At 2.7x Graham's Number, 98.7x P/FCF, 47x EV/EBIT, and declining normalized earnings — this stock does not screen as cheap by any conventional measure. The interest expense alone ($14M in FY2025, likely $60-80M in FY2026) threatens to eliminate operating income entirely. EPS could go negative in 2026-2027 as expansion costs peak. Investors who buy today may face 18-24 months of earnings disappointment before any recovery."
Moat Analyst rebuttal: "You're measuring LEU the wrong way. The $3.9B backlog covers the entire market cap — these are contracted revenues, not forecasts. The DOE just handed them a $900M task order. The Piketon expansion is being funded by already-raised capital ($742M net cash). The interest expense concern is valid but the market cap gives no credit for $742M in NET cash or $3.9B in contracted revenue. The stock should be worth more than the backlog alone."
Fundamentals mediates: "Both are right about different time horizons. In the next 4-8 quarters, earnings will be compressed and could go negative on a GAAP basis if interest charges absorb operating income. That's real risk and means choppy price action is likely. But by 2028-2030, when Piketon starts contributing revenue, the business economics flip dramatically. The $3.9B backlog plus expansion optionality creates substantial long-term value that current FCF metrics cannot capture."
Manager synthesis: The debate resolves on time horizon. For investors with a 2-year or shorter horizon, LEU is difficult — declining earnings, high debt, possible GAAP losses in 2026-2027. For investors with a 4-7 year horizon, the risk/reward is compelling: a monopoly infrastructure asset with government backing, contracted $3.9B in revenue, and a regulatory position that cannot be replicated. The key judgment: is this more like building a toll bridge (painful construction period, then decades of cash flow) or is there genuine execution risk that could strand the capital?
Assessment: Fluor as EPC + Geiger Brothers as construction + $300M identified cost savings + DOE as anchor customer = the execution risk is manageable. This is more like the toll bridge scenario.
Phase 4 — Final Verdict
Manager's Weighted Verdict
Rating: [7.5/10] — Add at Current Levels ($145–170)
Why 7.5: The thesis is strong enough (HALEU monopoly, $3.9B contracted backlog, $900M DOE award, Fluor/Geiger execution team, $742M net cash) that this deserves a high conviction rating despite near-term earnings headwinds. Moderated from 8+ because: - FY2026-2027 will likely show declining or negative GAAP EPS as interest charges and expansion costs peak - The 34% share dilution since FY2022 means per-share economics move more slowly than total company metrics - Execution risk remains (Piketon is first-of-its-kind at commercial scale)
Why NOT a "wait for Q2 results": The 52wk low was hit this week at $144.65. The stock is already pricing in significant execution risk at $157. Waiting for perfect clarity means missing the entry — and given the DOE anchor, the fundamental floor is well-supported.
A portfolio-specific passage was removed from the public build.
Key Metrics Summary
| Category | Metric | Value | Signal |
|---|---|---|---|
| Price | Current | $157.77 | 52wk low this week ($144.65) |
| Price | vs. ATH ($464.25, Oct 2025) | -66% | Repriced from speculative peak |
| Valuation | Market Cap | $3.09B | — |
| Valuation | EV (net of net cash) | $2.35B | — |
| Valuation | EV/Backlog | 0.60x | 🟢 Well below historical 0.8-1.5x range |
| Valuation | P/FCF | 98.7x | 🔴 Expensive on current FCF |
| Valuation | Graham's Number | $58.45 | 🔴 Does not apply (wrong model) |
| Backlog | Contracted Revenue | $3.9B | 🟢 Exceeds market cap |
| Backlog | Duration | To 2040 | 🟢 14-year visibility |
| Balance Sheet | Net Cash | +$742M | 🟢 Well-capitalized for expansion |
| Balance Sheet | Total Debt | $1.215B | 🟡 Elevated, manageable with net cash |
| Balance Sheet | Debt/Assets | 49.7% | 🟡 Moderate |
| Margin | Operating Margin | 11.2% | 🔴 Compressed from 20.5% (FY2022) |
| Margin | Gross Margin | 26.2% | 🔴 Compressed from 40.1% (FY2022) |
| Growth | Revenue CAGR (3yr) | 15.2% | 🟢 Solid |
| Growth | Diluted EPS CAGR (3yr) | 4.9% | 🟡 Diluted by share issuance |
| Dilution | Shares (FY2022→FY2025) | +34.3% | 🟡 Significant |
| Analysts | Consensus | 11B / 5H / 0S | 🟢 Overwhelmingly bullish |
| DOE | HALEU Contract | $900M | 🟢 Anchor customer |
| Moat | Evergreen Rating | 8/10 | HALEU regulatory monopoly |
Updated Watchlist Entry
- **LEU** — [7.5] — Centrus Energy Corp — (Avg: $205.97, Now: $157.77, G/L: -23.4%) |
Only U.S.-licensed HALEU producer. $3.9B backlog to 2040. $900M DOE HALEU contract (Jan 2026).
Piketon expansion underway with Fluor (EPC) + Geiger Brothers (construction).
$742M net cash; no liquidity risk. Near-term EPS compressed by interest + expansion costs.
**ADD ZONE: $145–170.** Strong buy $130–145 (near 52wk low). Trim $230–260.
Thesis break: DOE cancels HALEU, backlog <$2.5B, or equity raise <$150.
*Analyzed 2026-06-11.*
Sources: Yahoo Finance MCP (financials, price history, analyst consensus), PR Newswire (Centrus $900M DOE award), Fluor newsroom (EPC partnership), ANS Nuclear Newswire (Fluor + DOE $2.7B award), Motley Fool (Q1 2026 earnings, May selloff), Yahoo Finance / StockStory (June selloff), Seeking Alpha / SimplyWallSt (valuation), Centrus Q1 2026 8-K (SEC EDGAR), RA Capital investment thesis.